|
1）Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effects of point mutations in myelodysplastic syndromes. N Engl J Med. 2012; 364: 2496-506
|
|
|
|
2）Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478: 64-9
|
|
|
|
|
3）Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365: 1384-95
|
|
|
|
|
|
4）Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122: 3616-27
|
|
|
|
|
|
5）Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28: 241-7
|
|
|
|
|
|
6）Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011; 20: 11-24
|
|
|
|
|
|
7）Quivoron C, Couronne L, Della Valle V, Lopez, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011; 20: 25-38
|
|
|
|
|
|
8）Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011; 19: 17-30
|
|
|
|
|
|
9）Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2013; 18: 553-67
|
|
|
|
|
|
10）Sasaki M, Knobbe CB, Munger JC, et al. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012; 488: 656-9
|
|
|
|
|
|
11）Muto T, Sashida G, Oshima M, et al. Concurrent loss of EZH2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med. 2013; 210: 2627-39
|
|
|
|
|
|
12）Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012; 22: 180-93
|
|
|
|
|
|
13）Nikoloski G, van der Reijden BA, Jansen JH. Mutations in epigenetic regulators in myelodysplastic syndromes. Int J Hematol. 2012; 95: 8-16
|
|
|
|
|
14）Inoue D, Kitaura J, Togami K, et al. Myelodysplastic syndromes are induced by histone methylation-altering ASXL1 mutations. J Clin Invest. 2013; 123: 4627-40
|
|
|
|
|
|
15）Abdel-Wahab O, Gao J, Adli M, et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med. 2013; 210: 2641-59
|
|
|
|
|
|
16）Wang J, Li Z, He Y, et al. Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood. 2014; 123: 541-53
|
|
|
|
|
|
17）Xie H, Xu J, Hsu JH, et al. Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. Cell Stem Cell. 2014; 14: 68-80
|
|
|
|
|
|
18）Ogawa S. Splicing factor mutations in myelodysplasia. Int J Hematol. 2012; 96: 438-42
|
|
|
|
|
|
19）Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010; 42: 722-6
|
|
|
|
|
|
20）Przychodzen B, Jerez A, Guinta K, et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood. 2013; 122: 999-1006
|
|
|
|
|
|
21）Gentien D, Kosmider O, Nguyen-Khac F, et al. A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages. Leukemia. 2014; 28: 1355-7
|
|
|
|
|
|
22）Visconti V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndroems. Blood. 2012; 18: 3173-86
|
|
|
|
|
|
23）Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. Annu Rev Genet. 2009; 43: 525-58
|
|
|
|
|
|
24）Rocquain J, Gelsi-Boyer V, Adelaide J, et al. Alterations of cohesion genes in myeloid diseases. Am J Hematol. 2010; 85: 717-9
|
|
|
|
|
|
25）Welch J, Let TJ, Link D, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150: 264-78
|
|
|
|
|
|
26）The Cancer Genome Altlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059-74
|
|
|
|
|
|
27）Kon A, Shih LY, Minamino M, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet. 2013; 45: 1232-7
|
|
|
|
|
|
28）Yoshida K, Toki T, Okuno Y, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet. 2013; 45: 1293-9
|
|
|
|
|
|
29）Kemp CJ, Moore JM, Moser R, et al. CTCF haploinsufficiency destabilizes DNA methylation and predisposes to Cancer. Cell Reports. 2014; 22: 1020-9
|
|
|
|
|
|
30）Yamazaki J, Issa JP. Epigenetic aspects of MDS and its molecular targeted therapy. Int J Hematol. 2013; 97: 175-82
|
|
|
|
|
|
31）Lee WY, Chen KC, Chen HY, et al. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers. Biomed Res Int. 2014; 2014: 364625
|
|
|
|
|
|
32）Elhammali A, Ippolito JE, Collings L, et al. A high-throughput fluorimetric assay for 2-hydroglutarate identifies Zaprinast as a glutaminase inhibitor. Cancer Discov. 2014; 4: 828-39
|
|
|
|
|
|
33）Emadi A, Jun SA, Tsukamoto T, et al. Inhibition of glutaminase selectively suppresses the growth of primary acute leukemia cells with IDH mutations. Exp Hematol. 2014; 42: 247-51
|
|
|
|
|